91精品国产手机在线-白筒袜嫩萝双腿之间乳白液体-青青操手机在线视频观看-日本中文字幕人妻日韩-日韩精品在线观看视频网站-天堂资源中文最新版在线一区-欧美专区一区二区三区-国产综合亚洲欧美在线-国产精品久久久久久福利69堂

來蘇之望丨張小田教授:創(chuàng)新靶向聯(lián)合免疫,有望攻下晚期胃癌治療“堡壘”( 三 )


參考資料:
[1] Shen L, Lu M, Chen ZD, et al. Phase II trial of surufatinib plus toripalimabfor disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junctionadenocarcinoma.2021 ASCO. e16040.
[2] MoehlerM., Shitara K., Garrido M. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo)versus chemo as first-line (1L) treatment for advanced gastriccancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma(EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31:S1191.
[3] FukuokaS, Hara H, Takahashi N, et al. Regorafenib Plus Nivolumab in Patients WithAdvanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, andDose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun20;38(18):2053-2061.
[4] Lu M,Cao YS, Gong JF,et al. A Phase I Trial of Surufatinib plus Toripalimab inPatients with Advanced Solid Tumor. AACR 2020. Abstract No. 9563.
*此文僅用于向醫(yī)學(xué)人士提供科學(xué)信息 , 不代表本平臺觀點(diǎn)
【來蘇之望丨張小田教授:創(chuàng)新靶向聯(lián)合免疫,有望攻下晚期胃癌治療“堡壘”】

推薦閱讀